CORDIS
EU research results

CORDIS

English EN

Modelling and predicting sensitivity to targeted therapies in colorectal cancers

Objective

Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk and patient-response stratification criteria, which can then be used to rationally develop companion diagnostic assays and more stream-lined clinical trials. COLTHERES will address these key issues by:
1) Molecularly profiling colon cancer patient samples using multiple ‘omics based technologies for co-segregating lesions that could impart resistance to existing and emerging targeted therapies
2) The building and screening of predictive in vitro models based on this data, to enable the rapid and empirical determination of drug resistance biomarkers
3) The use of these models and of the clinical studies to prospectively screen for genes mediating resistance and sensitivity to targeted therapies in CRCs
4) The building of new algorithms to significantly accelerate the design of rational therapies, by integrating more predictive models, assays and biomarkers into all phases of drug discovery; including novel phase-0 (xenopatients) studies
5) The design of innovative and focused biomarker driven phase II trials based on knowledge gathered within the project

COLTHERES has assembled a unique consortium, from both academia and industrial SMEs, of world- experts in the areas of;
• clinical design of innovative biomarker trials and improved therapeutic strategies
• ‘omics technologies including genomic, transcriptomic, epigenomic and proteomic profiling
• Functional genomic and disease model-generation
• Bio-informatics and data analysis, to handle and interrogate the complexity of the data generated through the various approaches
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITA DEGLI STUDI DI TORINO

Address

Via Giuseppe Verdi 8
10124 Torino

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 507 200

Administrative Contact

Alberto Bardelli (Prof.)

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Spain

EU Contribution

€ 419 200

Horizon Discovery Limited

United Kingdom

EU Contribution

€ 920 520

Agendia NV

Netherlands

EU Contribution

€ 490 500

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 641 200

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON

Spain

EU Contribution

€ 333 900

AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA

Italy

EU Contribution

€ 314 800

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 498 400

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 348 700

SIB INSTITUT SUISSE DE BIOINFORMATIQUE

Switzerland

EU Contribution

€ 320 880

ARTTIC IN BRUSSELS SPRL

Belgium

EU Contribution

€ 204 000

Project information

Grant agreement ID: 259015

Status

Closed project

  • Start date

    1 January 2011

  • End date

    31 December 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 200 254,40

  • EU contribution

    € 5 999 300

Coordinated by:

UNIVERSITA DEGLI STUDI DI TORINO

Italy